The objective of this study was to investigate the associations among lung cancer location, and epidermal growth factor receptor (EGFR) mutation status. Treatment-naive, pathologically confirmed lung adenocarcinomas with tumor specimens available for genetic analysis were included from 2011 through 2014. Overall, 1771 patients with lung adenocarcinoma were included for analysis, after excluding those with carcinoma not otherwise specified, or synchronous multiple primary lung cancers. The median age was 64 years, and the female:male and never smoker:ever smoker ratios were 930:855 (52:48%) Carcinogenesis, 2016, Vol. 37, No. 2 and 1167:604 (65:35%), respectively. The EGFR mutation rate was 56%. Among patients, 1093 (62%) had primary tumors in the upper lobes. Compared with the characteristics of the EGFR wild-type, tumors with EGFR activating mutations were more common in women (P < 0.001), never smokers (P < 0.001), and in the upper lobes (P = 0.004). Among EGFR activating mutations, compared with the EGFR exon 19 deletion, L858R mutation were more common in women (P = 0.002), never smokers (P = 0.038), and the upper lobes P < 0.0005). The present study is the first to address that different pulmonary lobar locations might harbor different EGFR mutation subtypes. We demonstrated that adenocarcinomas with L858R mutation, rather than exon 19 deletion or wild-type EGFR gene, prefer to locate over the upper lungs. This phenomenon was more significant in females and never-smokers, implying the result of complex interactions between genetic susceptibility and environmental factors. Therefore, EGFR L858R mutation and exon 19 deletion may not be identical disease entity from the point of carcinogenesis.
Introduction
Lung cancer is the leading cause of cancer death worldwide (1) . The success of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitor therapies in patients with lung cancer who have EGFR mutations and EML4-ALK translocations initiated the era of targeted therapy for advanced non-small cell lung cancers (2, 3) and shifted treatment from platinum-based chemotherapy to molecularly targeted therapy.
In East Asia, there are several unique characteristics of lung cancer (4) , including the predominance of adenocarcinoma over other cell types and a large proportion of never-smoker and female patients. Such features may provide keys for further investigating the treatment and/or prevention of lung cancer in East Asians. Moreover, the incidences of activating mutations of oncogenic drivers in Western and Asian populations are different, especially with regard to the EGFR and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (5-7). The two most common EGFR mutations that have been identified, representing 85-90% of EGFR mutations, are the EGFR exon 19 deletion in the tyrosine kinase domain and an arginine for leucine substitution at amino acid 858 (L858R). Those EGFR mutations vary with respect to patient characteristics, response to tyrosine kinase inhibitors, and overall survival (8) (9) (10) . Several published studies have indicated that certain carcinogens and factors were related to the lobar distribution of lung cancer (11) (12) (13) (14) (15) (16) (17) . Inhaled carcinogens, such as from cigarette smoking, favor an upperlobe location for tumors (15) . On the contrary, individuals with circulating hazardous material may be more prone to lower-lobe tumors. One study found that people who consumed healthier foods were not only more likely to have a decreased incidence of lung cancer overall, but also an increased risk of upper-lobe tumors (16) . The main objective of this study was to investigate the associations among lung cancer location and EGFR mutations status.
Materials and methods

Study population
This multicenter, observational study was conducted in five medical centers in Taiwan, including Taichung Veterans General Hospital, National Taiwan University Hospital, China Medical University Hospital, Chung Shan University Hospital and Taichung Tzu Chi Hospital. In Taiwan, genetic analysis is our standard pre-treatment evaluation for every patient with lung adenocarcinoma. Those five medical centers routinely provided available tumor specimens to National Taiwan University Center of Genomic Medicine for genetic analysis, and the results were send back to original hospital for treatment plan. We collected genetic analysis results from National Taiwan University Center of Genomic Medicine and patient characteristics from five medical centers. To be eligible for the study, patients were required to have treatment-naive and pathologically confirmed lung adenocarcinoma and available tumor specimens for genetic analysis. Patients were excluded if they had lung cancer with histology other than adenocarcinoma, including those with carcinoma not otherwise specified, synchronous multiple primary lung cancers, or other active malignancy. Demographic characteristics and lifestyle variables, including age, gender and cigarette smoking status (never-smokers were defined as patients who had never smoked cigarette, whereas ever-smokers defined as those who were current or former smokers), were collected by questionnaire interview.
This study was approved by the Institutional Review Board of the participating institutes. Written informed consent for genetic testing and use of clinical data records was obtained from all patients.
Biomarker analysis
Five oncogenic drivers, including EGFR, KRAS, BRAF, HER2 and EML4-ALK, were tested. EGFR, KRAS, BRAF and HER2 mutations were assessed by matrix-assisted laser desorption ionization-time of flight mass spectrometry. EML4-ALK translocation was tested by Ventana method in patients with EGFR-wild-type lung adenocarcinoma (18 
Classification of tumor location
We reviewed chest computed tomography (CT) images to identify the location of the primary tumor. The right upper, right middle and left upper lobes were classified into the 'upper-lobe' group. The right lower and left lower lobes were included in the 'lower-lobe' group.
Statistical analyses
Statistical analysis was aimed at identifying the different factors associated with the EGFR mutation type and lobar location. Clinical data used in analysis included patients' age, sex, tumor stage and smoking status. TNM (tumor, node and metastases) staging was done according to the 7th edition of the American Joint Committee for Cancer (AJCC) staging system (19) . Chest CT images, which included the liver and adrenal glands, were reviewed by two chest physicians. EGFR mutation types were first cross-tabulated with age, sex, smoking variables, stage and tumor location. Associations between mutation type and continuous variables, such as age, were assessed using Student's t test. Associations between mutation type and categorical variables were assessed using the Pearson's chi-squared test or Fisher's exact test. Logistic regression analysis was adopted to assess lobar location and clinical factors. All analyses were performed using Stata (version 13.0, Stata Corporation, TX).
Abbreviations
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Results
Patient characteristics
We enrolled 1973 consecutive patients with newly diagnosed lung adenocarcinoma from 2011 through 2014. All patients had an EGFR mutation at the time of biopsy or surgery. In total, 1771 patients were included for analysis after excluding those with carcinoma not otherwise specified, synchronous multiple primary lung cancers, or other active malignancy. The descriptive characteristics according to sex, age, smoking status and tumor stage included in the analysis are summarized in Table 1 . The median age was 64 years (range, 21-102 years). There were slightly more female patients (n = 926, 52.3%) than there were male patients (n = 845, 47.7%). Never smokers (n = 1159, 65.4%) were predominant. The majority of patients had late-stage cancer (stage IV, n = 1114, 64.2%). The EGFR mutation rate was 55.5%. Among the patients, 1093 (61.7%) had primary tumors in the upper lobes, and 678 (38.2%) had them in the lower lobes. Besides, the number of subjects and patient characteristics in each five medical centers are summarized in Supplementary Table 2 , available at Carcinogenesis Online and age, sex, EGFR mutation rate and tumor location were not different significantly.
Patients' characteristics and EGFR mutation status
A further characterization of tumors according to EGFR mutation status based on a univariate analysis is presented in Table 2 . Compared with those with no detected EGFR mutation, tumors with EGFR activating mutations were more common in women (P < 0.001), never smokers (P < 0.001), and the upper lobes (P = 0.004). There was no significant difference in age or tumor stage among these subgroups.
Tumor location and EGFR mutation subtype
Compared with lower-lobe tumors, upper-lobe tumors were more likely to have an EGFR mutation ( Table 2 , P < 0.004). In addition, the mutation subtypes were also significantly different with respect to lobar distribution (Table 3 , P < 0.001).
Among EGFR activating mutations, L858R mutations were more prevalent in upper-lobe adenocarcinomas than they were in lower-lobe adenocarcinomas (31.4% versus 19.8%).
In the multiple logistic regression analysis, after adjusting for sex and smoking status, we found that adenocarcinomas with the L858R mutation were twice as likely to occur in the upper lobes than average ( All data are presented as n (%). 
Sensitivity analysis for tumor location and EGFR mutation subtype
In our cohort, 94.5% of women were never smokers. The two covariates, sex and smoking status, were highly collinear (aOR, 13.9; 95% CI, 9.6-20.3). Instead of using a multiple logistic regression analysis, we stratified patients by sex for further analysis. In male patients, only tumors with the L858R mutation were more likely to be located in the upper lobes than average ( 
EGFR mutation profiles for upper-and lower-lobe adenocarcinomas
In the above analysis, we found that female sex, never smoker status and EGFR L858R mutation were significantly related to upper-lobe location. Figure 1 shows the stratification of these factors. In the upper panel, all patients were classified into the upper and lower bars based on their primary tumor's lobar location; the EGFR mutation profiles were presented separately. ). In the lower panel, only never-smokers were included. Tumors with the L858R mutation were more likely to occur in the upper lobes for all subgroups. On the other hand, the ever-smokers have lower EGFR mutation rate, but the upper-lobe preference was consistent with never-smokers (Supplementary Figure 1 is available at Carcinogenesis Online).
Discussion
In lung adenocarcinoma, women, never smokers and upperlobe tumors were more likely to have EGFR mutations, especially L858R mutations. The EGFR mutation rate was lowest in men with lower-lobe adenocarcinoma (47%) and highest in women with upper-lobe adenocarcinoma (71%). Lung cancer in never smokers is an increasingly prominent public health issue. Although the etiology of lung cancer among never smokers is not always clear, risk factors include second-hand smoke; occupational exposure to asbestos, radon, outdoor and indoor air pollution; diet; hormonal factors; genetic factors; and viral factors (20, 21) . To date, no major factors have been determined; however, the majority of this population carry activating mutations of the EGFR gene. EGFR mutant lung cancers may represent a distinct subclass of lung cancers, and typical mutations, especially L858R, have even been associated with aggressive behavior (22) . Lobar distribution may provide some clues as to the characteristics of the causal carcinogen. As a consequence of the effect of gravity, ventilation and perfusion predominate in the lower lungs. From apex to base, the blood flow increased more than ventilation, thus the ratio of ventilation-to-perfusion decreased. The physiologic results are the upper lungs are relatively overventilated and the lower lungs are slightly overperfused. Although inhaled pathogens are more likely delivered to the dependent lung, the higher ratio of ventilation-to-perfusion and less lymphatic clearance are important in the pathogenesis of apical lung disease. Several well-known respiratory diseases follow this rule. Inhaled noxious gases, such as cigarette smoke, trigger neutrophil release of proteases and our protection is effected by antiproteases. The balance between lung destruction and protection dependent on the ratio of ventilation-to-perfusion, thus centrilobular emphysema primarily involves the upper lungs. Inhaled dust particles may cause pneumoconiosis in pulmonary lobes with poor ability to degrade and remove them. The most intense reaction occurs more in the upper lobes. Many chronic granulomatous disorders (tuberculosis, sarcoidosis, eosinophilic granuloma, chronic histoplasmosis and farmer's lung) have their initial episodes of hypersensitivity pneumonis in the lower lung and chronic granulomatous destruction predominates in the upper lobes because enhanced lymphatic flow clears the lower lung.
Traditionally, we believed that lung cancer occurred predominantly in the upper lobes (11) . Some theories had been proposed in the literature. First, particles deposit more readily in the upper lobes, and once the carcinogens or toxins are inhaled, they may persist longer in the upper lobes due to less relative ventilation or less efficient lymphatic clearance. Additionally, higher tissue PO 2 levels in the upper lobes might help with tumor initiation, and small nests of cancer cells might be able to survive for longer periods of time before being required to induce neovascularization (23, 24) . Second, several studies found that high consumption of fruit, vegetables and fish decreased the risk of lower-lobe lung cancer among never smokers (21) . The upper-lobe predominance of lung cancer may be, in part, due to less efficient delivery of diet-derived or other protective substances via circulation to the upper lobes compared with that to the lower lobes (16) . In our study, the EGFR L858R mutation occurred more often in upper-lobe tumors than did exon 19 deletion and the wild-type EGFR gene, which may imply a different etiology between these activating EGFR mutations.
One study suggests that female smokers are at a higher risk for developing lung cancer than male smokers (25) . In our analysis, female never-smokers with lung adenocarcinoma were more likely to have the L858R mutation in the EGFR gene than they were to have the exon 19 deletion. Additionally, women with L858R mutations were more likely to have adenocarcinomas occurring in the upper lobes. Such as cigarette smoking related emphysema, pulmonary tuberculosis and pneumoconiosis, L858R-related adenocarcinomas also predominates in the upper lobes. It can be inferred that L858R-related carcinogens might enter the lungs through inhalation and may more easily affect women. In a review study by Samet et al., many lung cancer risk factors in never-smokers were discussed. Among those factors, L858R mutation is more likely to be related to those inhaled carcinogens as follows: (i) outdoor air pollution from the combustion of fossil fuels, (ii) indoor air pollution due to cooking fumes in the household, or indoor coal burning, or inhaled pathogen, and (iii) respiratory microorganisms, such as Chlamydia pneumoniae (21) . In our previous genome-wide association study of 584 patients and 585 controls from Taiwan, the CLPTM1L-TERT SNP in rs2736100 on chromosome 5p15.33 was identified as a susceptibility SNP associated with lung adenocarcinoma in never-smoking women (26) . Furthermore, three new susceptibility loci at 10q25.2 (rs7086803), 6q22.2 (rs9387478) and 6q21.32 (rs2395185) were identified in a multi-stage genome-wide association study of 5510 never-smoking female lung cancer patients and 4544 controls from 14 studies from Asia (27) . In a study by Nose et al. (28) , a strong nuclear expression of ER-β was independently associated with the EGFR mutations and correlated with an increasing disease-free survival in patient with EGFR mutation. Another study by Rouquette et al., a higher rate of EGFR mutations and ERα expression in women was observed (29, 30) . In our previous study, we also demonstrated that the L858R mutation of the EGFR gene is associated with polymorphisms in genes related to estrogen biosynthesis and metabolism in never-smoking women with lung adenocarcinoma (31) . These associations might imply that genetic factors could interact with carcinogens, especially inhaled carcinogens.
Our study had some limitations. First, 94.5% of women were never smokers in our study; thus, we could not determine whether the lower-lobe preference was definitively due to the 'female' or 'never-smoker' effect. Second, Kinsey et al. (14) defined lung regions by automated segmentation into equal volumetric thirds for better ventilation-perfusion correlation. In our study, we used traditional lobe definitions, which might not be adequate for explaining inhalation carcinogenesis. Third, in a study by Suzuki et al. (32) showed significant dose-response relationship between tobacco smoke and TP53 mutations in patients with non-small-cell lung cancer. Our current data lacks TP53 mutations status. Knowing whether TP53 mutations also associates with lobe status would help us to understand the possible significance of EGFR mutations in environmental carcinogenesis. The present analysis revealed that the L858R mutation was more likely to occur in women and in the upper lobes. These characteristics were significantly different from those associated with the EGFR exon 19 deletion and the wild-type EGFR gene. These findings suggest that L858R mutation and exon 19 deletion might not be due to an identical disease entity, and they may have different treatment responses and different etiologies.
Supplementary material
Supplementary Figure 1 and Supplementary Tables 1-3 can be found at http://carcin.oxfordjournals.org/
